Tajikistan’s health ministry denies claims linking Pantogam drug to child deaths
Tajikistan’s Ministry of Health and Social Protection of the Population (MoHSPP) has denied claims that the drug Pantogam is harmful or linked to the deaths of children, stating that reports circulating on social media are unfounded and lack medical evidence.
In recent days, social media posts alleged that Pantogam had caused health complications in children with neurological conditions and had led to fatal outcomes.
According to a MoHSPP, following the spread of this information, the State Health Control Service conducted additional laboratory tests and quality inspections. The results confirmed that the drug, manufactured by the Russian pharmaceutical company Pik-Pharma Lek LLC, fully complies with quality and safety standards required for medicines distributed in Tajikistan.
Medical specialists from the ministry, including toxicologists and neurologists, said there is no scientific basis for claims that Pantogam could cause the deaths of children with nervous system disorders. They noted that the drug is approved for use and has official instructions, and that when taken in accordance with medical recommendations, the risk of side effects is minimal.
The ministry emphasized that, like any medication, Pantogam has contraindications and must be used strictly as prescribed. Failure to follow instructions may result in side effects such as headaches or sleep disturbances. It was also noted that prolonged use of the drug in combination with other nootropic medications and stimulants may be undesirable.
The Health Ministry also reported that a social media claim made by a citizen alleging that two of his children had died and one had been hospitalized after taking Pantogam was investigated and found to be unsubstantiated.
According to official information, the complainant, Komiljon Latipov, brought his four-month-old daughter, Zakiya Komiljonzoda, to the pediatric department of Istiqlol Hospital on January 10 with symptoms including drowsiness, lethargy, general weakness, cold extremities, and vomiting. The child’s parents suggested that their daughter’s condition may have worsened after taking the drug Pantogam. In addition, Komiljon Latipov claimed that three children had allegedly died as a result of using the medication; however, no such cases have been recorded by medical institutions, the MoHSPP said.
Doctors diagnosed the infant with toxic encephalopathy with signs of central nervous system depression and admitted her for treatment. Her condition is currently reported as stable.
The Ministry of Health urged citizens to be cautious and to rely only on official sources for information regarding medicines and healthcare services.
For questions or concerns related to the use of medications, citizens are advised to contact the health ministry’s hotlines: +992 888 000 303; +992 931 119 191; and +992 37 250 35 33.
In recent days, social media posts alleged that Pantogam had caused health complications in children with neurological conditions and had led to fatal outcomes.
According to a MoHSPP, following the spread of this information, the State Health Control Service conducted additional laboratory tests and quality inspections. The results confirmed that the drug, manufactured by the Russian pharmaceutical company Pik-Pharma Lek LLC, fully complies with quality and safety standards required for medicines distributed in Tajikistan.
Medical specialists from the ministry, including toxicologists and neurologists, said there is no scientific basis for claims that Pantogam could cause the deaths of children with nervous system disorders. They noted that the drug is approved for use and has official instructions, and that when taken in accordance with medical recommendations, the risk of side effects is minimal.
The ministry emphasized that, like any medication, Pantogam has contraindications and must be used strictly as prescribed. Failure to follow instructions may result in side effects such as headaches or sleep disturbances. It was also noted that prolonged use of the drug in combination with other nootropic medications and stimulants may be undesirable.
The Health Ministry also reported that a social media claim made by a citizen alleging that two of his children had died and one had been hospitalized after taking Pantogam was investigated and found to be unsubstantiated.
According to official information, the complainant, Komiljon Latipov, brought his four-month-old daughter, Zakiya Komiljonzoda, to the pediatric department of Istiqlol Hospital on January 10 with symptoms including drowsiness, lethargy, general weakness, cold extremities, and vomiting. The child’s parents suggested that their daughter’s condition may have worsened after taking the drug Pantogam. In addition, Komiljon Latipov claimed that three children had allegedly died as a result of using the medication; however, no such cases have been recorded by medical institutions, the MoHSPP said.
Doctors diagnosed the infant with toxic encephalopathy with signs of central nervous system depression and admitted her for treatment. Her condition is currently reported as stable.
The Ministry of Health urged citizens to be cautious and to rely only on official sources for information regarding medicines and healthcare services.
For questions or concerns related to the use of medications, citizens are advised to contact the health ministry’s hotlines: +992 888 000 303; +992 931 119 191; and +992 37 250 35 33.
Комментарии (0)